Company intelligence / Profile preview

EndoGene.Bio

Évry/Paris area, Île-de-France, France

Ownership: Private
Development stage: Other

Overview

EndoGene.Bio is developing a novel, non-invasive diagnostic tool for early detection of endometriosis using epigenetic markers from menstrual blood. The company aims to reduce the average time to diagnosis from seven years to two consultations by enabling at-home sample collection and rapid analysis. Early proof-of-concept validation is ongoing in partnership with hospitals[2][3].

Therapeutic areas: Women's Health
Modalities: Diagnostic test (based on epigenetic biomarkers)
Industry: Molecular Diagnostics

Partnerships

Two hospital partners for clinical proof-of-concept validation[2]Entrepreneur First accelerator/investor[2][3]

Beyond the preview

Go deeper on EndoGene.Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoGene.Bio.

Explore the full profile